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Background
We are in a period of unprecedented
scrutiny of the relationships between the
pharmaceutical industry and doctors
[1–4]. Legislators are now considering
how they might become involved in the
regulation of these practices. This is a
telling comment on the perceived failure
of the medical profession to regulate itself
and of self-regulation by industry. But
reliable and comprehensive data on the
nature and extent of industry sponsorship
are rare. Several states in the US have
mandatory disclosure laws for physician
payments, but these data have proved
difficult to access and analyse [5]. The US
Congress is considering new mechanisms
for revealing industry–professional inter-
actions (the so-called ‘‘Sunshine’’ Acts)
[6,7].
One of the first countries to move
towards greater transparency was Austra-
lia. The pharmaceutical industry repre-
sentative body, Medicines Australia, has a
self-regulatory Code of Conduct that sets
standards for the ethical marketing and
promotion of prescription pharmaceutical
products for its member companies. In
addition to monitoring of promotional
activities, a Code of Conduct Committee
adjudicates on complaints regarding phar-
maceutical company activities [8]. In
2007, the Australian Competition Tribu-
nal placed disclosure requirements on
Medicines Australia. It approved that
body’s Code of Conduct for industry–
professional relationships on the condition
that details of every sponsored event,
including the costs of any hospitality, were
posted on their website [9,10]. Reporting
commenced in July 2007 and data are
updated six monthly [8].
In this Policy Forum we examine the
Australian data and argue that although
a definite advance, the Australian disclo-
sure requirements fall short of what is
required. We propose more comprehen-
sive reporting standards, which should
have application to other settings and
jurisdictions.
Australian Experience of
Pharmaceutical Company
Disclosures
In Australia, the emphasis in disclosure
is on monitoring the level and type of
sponsorship of educational events rather
than documenting the dollar value of gifts
and other payments to physicians. Since
2007 pharmaceutical companies have
been required to report all functions
(educational events) provided or sponsored
for health professionals. They are required
to disclose the following: the venue; the
professional status of attendees; a descrip-
tion of the function and duration of the
educational content of events; the nature
of the hospitality; the total cost of
hospitality; the numbers of attendees;
and the total cost of the function [11].
The first report, covering the period
July to December 2007, provided details of
14,649 events (Table 1) [12]. This total is
equivalent to almost 600 events per week
nationally, at a cost of around AUD$1
million/week (US$879,074.00). Put an-
other way, the pharmaceutical industry
spends, on average, around AUD$1,000
annually on each doctor through sponsor-
ship of such events. The top five compa-
nies in terms of the numbers of sponsored
events were Astra Zeneca, Pfizer, Sanofi
Aventis, Janssen Cilag, and Eli Lilly
(Table 1). The most generous of the active
companies (those with .100 functions in 6
months) was Bristol Myers Squibb, with an
average cost per head of AUD$95.26. In
contrast, Alphapharm (a generics manu-
facturer) sponsored 441 events (mostly in
professional rooms with a sandwich lunch)
at an average cost per head of AUD$18.24
(Table 1).
Hospitality (food, beverages, travel,
accommodation) accounted for around
AUD$17 million of the total of AUD$31
million spent on functions. Thirty-five
percent of sponsored events (n=5,174)
were held in restaurants, hotels, or func-
tion centres. The average cost per head
was much higher when the venue was a
restaurant (AUD$71.35) than in a hospital
(AUD$12.11). In 7.2% of cases (n=1,062)
expenditure exceeded AUD$100 per head
(examples are given in Box 1). There were
74 events (0.5%) with total outlays per
head on hospitality in excess of AUD$500.
Medical specialists were present at 62%
(n=9,018) of events, family physicians at
30% (n=4,437), nurses at 26% (n=3,820),
and pharmacists at less than 5% (n=621)
of events. Registrars (medical specialists in
training) were present at 19% (n=2,827)
of events; in 179 instances they were the
only attendees. The medical subspecialties
most often featured were psychiatry
(17.9%), and oncology (15.2%), who
received industry hospitality roughly three
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(Table 2). The largest per head expendi-
ture was directed at endocrinologists,
oncologists, and cardiologists (Table 2).
Companies spent considerably more on
restaurant meals for doctors (AUD$76.73)
than for nurses (AUD$48.78).
Companies reported no responsibility
for the educational content in only 9% of
events (n=1,287). Likewise, continuing
medical education (CME)/continuing pro-
fessional development (CPD) points were
allocated to 9% of events (n=1,270). Just
over 20% of all events were described as
‘‘journal club’’ or ‘‘grand rounds’’
(n=3,035), mostly conducted in hospitals.
The majority of events (n=10,723, 73.2%)
were a mix of meetings of various kinds,
including workshops and in-service train-
ing activities; only 4% (n=591) were
described as ‘‘conferences.’’ Table 3 shows
the topics discussed, the most common
being cardiology, diabetes, oncology, psy-
chiatry, and respiratory medicine. The
most common specific topics were hyper-
tension, osteoporosis, breast cancer, type-2
diabetes, and depression. All represent
large and important markets for pharma-
ceutical products. Topic descriptions,
where provided, often matched the prod-
uct portfolio of the sponsor, although there
were few mentions of specific drug names
(n=582, 4%).
Importantly, Australian companies are
not required to disclose the names of the
speakers, whether sponsors played a role
in their selection or in the choice of the
content of presentations. They are also not
required to disclose the nature of any
financial ties between their companies and
the speakers.
Why Do We Need Better
Disclosure?
The information provided by Medicines
Australia points to a high level of contact
between pharmaceutical manufacturers
and health professionals, particularly doc-
tors. The per-person expenditure was
greatest for medical specialists who pre-
scribe high cost drugs—oncologists, endo-
crinologists, and cardiologists. Generally,
expenditure at individual events was
modest; however the cumulative expendi-
ture and the overall level of contact was
high. The available information suggests
that companies exert influence over the
educational content of events in most
cases, and doctors in training are often
present at these functions. There is
substantial evidence that attendance at
company-sponsored events modifies pre-
scribing practices [13–15]. The presence
of doctors in training and students (in
hospital-based sessions) may lead to a
process of enculturation whereby they
come to regard repeated contact with
pharmaceutical companies as a normal
and acceptable part of their professional
practice. The data reviewed here indicate
that, from a company perspective, it is
cheap and easy to sponsor meetings in
hospitals and health centres, and the
return on this ‘‘investment’’ is likely to be
high. Equally, it is straightforward for
administrators to limit sponsorship of such
activities, should they choose to do so. It is
difficult to see a role for pharmaceutical
companies at hospital grand rounds.
The evidence from this analysis of
Australian data suggests that disclosure
requirements should not stipulate thresh-
olds—set dollar amounts below which
disclosure is not required. Physician-report-
ing requirements such as those in Vermont
and Minnesota in the US, which exempt
payments of less than US$100, could
obscure the broad cumulative influence of
a number of smaller payments [5,16]. The
literatureindicatesthat itis notonly thesize
of the gift that matters—it is the sense of
reciprocity that it engenders [17].
The types of activities described here
need to be viewed within the broader
context of other forms of pharmaceutical
industry interaction with doctors, includ-
ing face-to-face contact with representa-
tives, advertising in medical journals,
consultancies, membership of advisory
boards, and stock holding [18–20]. While
lavish gifts and generous travel support
have been a focus of attention in the past,
these have been progressively discouraged
by industry and professional guidelines. It
is likely that the frequent, more modest,
sponsored educational events will become
increasingly important and influential, and
the principal form of contact between
industry and health professionals.
There are a number of organisations that
will benefit from more comprehensive
disclosure of these activities. Professional
organisations and accreditation bodies will
have accurate data on the level and type of
contact their members have with pharma-
ceutical companies. This will enable them to
counter the undesirable effects of such
relationships through the development of
guidelines, or the evolution of practice
standards or disciplinary codes. They will
benefit from sequential data to determine if
practices are changing over time. The
public, the media, and consumer groups
will have access to reliable data on which to
base their judgements about industry-health
professional contact and, when appropriate,
to lobby for change. Individual health
professionals could have access to informa-
tion on which to judge their own practices
against those of their peers. If legislation is
thought necessary, governments will have
data on which to monitor its impact.
Proposals for Greater
Transparency
The Australian reporting standards are
deficient in not including details that enable a
judgement about the educational value of
company sponsored events. We believe that
reporting schemes should require the follow-
ing details: the names of the speakers
presenting, whether sponsors played a role
in suggestion or selection of speakers or the
development of the content of presentations,
and the nature of any direct or indirect
Summary Points
N There are moves internationally to ensure greater disclosure of gifts and
educational events for doctors paid for by pharmaceutical manufacturers.
However, there is no agreement on appropriate standards of disclosure. In
Australia, since mid-2007, there has been mandatory reporting of details of
every industry-sponsored event, including the costs of any hospitality provided.
N Examination of the Australian data shows that although expenditure at
individual events is often modest, cumulative expenditure is high, particularly in
the case of medical specialists prescribing high cost drugs—oncologists,
endocrinologists, and cardiologists.
N Although a significant advance, the new Australian reporting standards do not
allow assessment of the educational value of sponsored events, and do not
include details of speakers or educational content for most events. However,
doctors in training are often present at these events.
N At present, the standards of disclosure are inadequate and should not be tied to
an arbitrary monetary value of gifts or sponsorship. Reporting standards should
require the names of the speakers presenting, whether sponsors played a role
in suggestion or selection of speakers or the development of the content of
presentations, and the nature of any direct or indirect financial ties between the
speakers and the sponsors.
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Company Events Reported (n) Details of Company-Sponsored Functions
a (% of All Functions Sponsored by the Company)
Journal Club or
Grand Rounds
Hospital or
Professional Rooms
Restaurant, Hotel, or
Function Centre
Average Cost/Head (AUD$)
Spent on Hospitality
AstraZeneca 1,310 43.0 61.3 35.1 $40.37
Pfizer 1,266 38.9 52.5 41.4 $34.81
Sanofi Aventis 1,119 21.6 66.8 29.0 $48.12
Jannsen Cilag 1,080 28.6 64.2 32.4 $33.96
Eli Lilly 940 17.4 60.2 38.1 $47.38
Novartis 927 10.4 79.9 17.7 $56.22
Roche 776 18.3 78.0 18.9 $29.25
GlaxoSmithKline 738 18.6 57.6 37.0 $37.24
Merck Sharp Dohme 734 20.0 74.0 23.6 $26.81
Servier 608 8.6 57.7 39.8 $48.35
Wyeth 501 26.7 45.7 51.9 $56.33
Alphapharm 441 0.0 89.3 10.7 $18.24
Merck Serono 397 6.8 77.8 15.6 $18.78
Novo Nordisk 372 13.4 73.9 23.4 $22.65
Amgen 357 22.4 68.3 27.2 $43.55
Boehringer Ingelheim 340 0.0 0.3 99.1 $69.80
Organon 275 17.1 49.5 46.5 $42.58
Abbott 249 16.5 75.5 22.5 $31.18
Mundipharma 205 37.1 57.6 36.1 $32.76
Schering Plough 190 15.8 23.2 74.2 $65.24
Nycomed 165 14.5 15.2 77.6 $77.10
Bayer 158 3.8 34.8 59.5 $47.44
Allergan 155 0.0 29.0 58.7 $55.09
BristolMyersSquibb 151 0.0 15.2 76.8 $95.26
The educational event reports were downloaded as pdf files and converted into Excel spreadsheets; a coding scheme was devised by two authors (EW and JR). The codes
were designed to differentiate the events based on: the duration; type of event; whether there were continuing professional development (CPD) or medical education
(CME) points awarded; the venue; the professional status of attendees; the hospitality provided; and the cost of the hospitality. A number of companies specifically stated
they were ‘‘not responsible’’ for the educational content of some events and we coded separately for these. The ‘‘not responsible’’ code included descriptors such as ‘‘topic
set by hospital,’’ ‘‘third party organisation,’’ ‘‘external training company,’’ or ‘‘sponsorship only.’’ A series of primary analyses were conducted in Excel, providing descriptive
statistics about the events sponsored by each company, and overall summary statistics. Ethics approval was not required to examine these publicly available data.
aAn independent audit of the first posting of educational events was commissioned by Medicines Australia, with 951 events identified as requiring review. Further
information was requested on 312 events with 52 referred to the Code of Conduct Committee. Twenty-four events were found to be in breach of the Code, this
number reduced to 21 after appeals of the decision [23].
doi:10.1371/journal.pmed.1000128.t001
Box 1. Five examples of high-cost sponsored events.
1. Flights, accommodation, food, beverages, and conference registration fees for six ophthalmologists to attend a two-day
conference in Spain, at a cost of AUD$10,993 per person, sponsored by Novartis.
2. One-hour cocktail party for 45 respiratory physicians on the Gold Coast, with hospitality costs of more than AUD$20,000,
including flights and accommodation for one speaker, sponsored by Actelion.
3. A presentation by a Key Opinion Leader exploring the link between diabetes, severe mental illness, and antipsychotics for
better patient management for 115 psychiatrists, general practitioners, and allied mental health workers at the RACV Club
a in
Melbourne with a hospitality cost of AUD$186 a head sponsored by Eli Lilly. This amount included travel, accommodation,
and extra meals for the speaker and 11 delegates.
4. Ten infectious diseases specialists given AUD$1,000 each, to contribute to flights, accommodation, and registration for a
conference at Conrad Jupiter’s Casino, Gold Coast, sponsored by Novartis.
5. Eight general practitioners attended an event with 2 hours of education at the Truffleduck restaurant in Perth, and earned 30
CPD points, with hospitality costs of almost AUD$140 a head, sponsored by Merck.
aRoyal Automobile Club of Victoria.
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sponsors. This type of information is routinely
requested by professional journals; so there
are ample precedents and it is particularly
relevant when judging the appropriateness of
educational events.
We experienced considerable difficulty in
accessing the Australian data, which are
compiled in portable document format
(pdf). As suggested in the US Sunshine Acts
it is important that summary reports listing
each function are accessible to the public in a
searchable, downloadable, and analysable
format [5–7].
Whether there should be a central register
or database that identifies attendees at
company-sponsored functions is more con-
troversial. The data could be compiled from
the records of names collected by the
pharmaceutical companies. Reports could
be provided to health professionals, which
would enable them to compare their practices
with their peers. We are not here advocating
public disclosure of this information, but
individuals could be asked to provide reports
in particular circumstances—for instance
when ethics committees are considering the
industry ties of an investigator.
In Box 2 we have summarised the main
data elements that we think should be
included in disclosure programs. What we
suggest is consistent with the recent Institute
of Medicine (IOM) Report on conflicts of
interest [21]. This report recommended that
the US Congress create a national program
requiring companies and their foundations to
publicly report payments to physicians and
other prescribers, biomedical researchers and
their institutions, but did not suggest specific
data elements. Some authors of the report
argued that this database should also provide
explanatory material about payments re-
ceived (e.g., for an educational or marketing
purpose) and information on all financial ties
(e.g., equity ownership, patent rights) in
addition to industry payments and gifts [22].
While it may be unrealistic and unde-
sirable to ban contact between pharma-
ceutical companies and health profession-
als we should work to make those
relationships completely transparent. We
welcome further debate on this topic.
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Table 2. Details of events where only specialists were present (n=3,377 events).
Specialty Number of Events Percent
Average Cost/Head (AUD$)
Spent on Hospitality
Psychiatry 606 17.9 $49.14
Oncology 514 15.2 $71.53
Surgery 221 6.5 $15.73
Cardiology 193 5.7 $70.50
Anaesthesiology 175 5.2 $26.58
Neurology 170 5.0 $63.11
Endocrinology 166 4.9 $71.77
Haematology 156 4.6 $41.76
Pathology 148 4.4 $14.16
Radiology 138 4.1 $12.44
doi:10.1371/journal.pmed.1000128.t002
Table 3. Ten most commonly reported
topic areas covered in company-
sponsored events.
Area
a n
Cardiology 1,085
Hypertension 266
Lipid lowering 112
Pulmonary arterial hypertension 69
Diabetes 1,075
Type 2 diabetes 192
Insulin and devices 107
Type 2 diabetes: blood pressure control 55
Oncology 1,041
Breast cancer 193
HPV/cervical cancer 101
Colorectal cancer 68
Prostate cancer 59
Psychiatry 967
Depression 170
Psychosis 99
Bipolar disorder 84
Respiratory 588
Asthma 143
Chronic Obstructive Pulmonary Disease 71
aEach event could cover more than one topic.
HPV, human papillomavirus.
doi:10.1371/journal.pmed.1000128.t003
Box 2. Details to be included in mandatory reporting schemes
for pharmaceutical industry–sponsored events for health
professionals.
Included in existing reports from Medicines Australia
The numbers of attendees and their professional status
The venue, and a description of the function
The nature of any hospitality provided
The total cost of hospitality and the total cost of the function
The nature of any entertainment provided
The duration of the educational content of events
Continuing professional development (CPD)/continuing medical education (CME)
points provided
Suggested additional compulsory reporting items
The nature of any gifts provided
The names of speakers
Dollar value of honoraria and travel support provided to speakers
Disclosure of other financial ties between sponsoring companies and speakers
(e.g., equity ownership, consultancies, advisory panel membership)
The role of the company in suggesting/choosing the educational topic and
speaker
The brand names of drugs discussed in the session
For debate
Registration of all attendees (limited access [Information available only to the
individual and through him or her to other bodies])
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